Skip to main content
. 2020 Jan 16;2020(1):CD012093. doi: 10.1002/14651858.CD012093.pub2

Stein 2014.

Methods RCT (parallel)
Study design: Double blind
Sample size calculation: Unknown
Diagnosis mycology: KOH and culture
Big toenail specified: Yes
Statistical comparisons for outcomes: Unknown
Duration of follow‐up: 4 weeks
Time points of measurements: Week 52
Location: United States (city/institution unknown)
Participants Total n: 334
Age: 18 ‐ 70 years of age, inclusive
Sex: Men and women (ratio unknown)
Inclusion criteria: Adult men and women, any race, 18 ‐ 70 years of age with a clinical diagnosis of mild‐to‐moderate distal subungual onychomycosis, 25% ‐ 50% nail involvement and positive KOH and culture. Participants had to be free of disease that in the investigator's opinion might interfere with study evaluations or jeopardise patient safety
Exclusion criteria: History of intolerance or hypersensitivity to imidazole compounds or the inactive components of the solution. Current or recent participation in another investigational medication or device study
Disease duration: Unknown
Comparable at baseline: Unknown
Causative species: Unknown
Number of participants lost to follow‐up: Unknown
Trial duration: unknown
Interventions Drug in study arm 1: Luliconazole solution, 10% once daily for 48 weeks, n = unknown
Drug in study arm 2: Vehicle solution, once daily for 48 weeks, n = unknown
Drug in study arm 3: Luliconazole solution, 10% once daily for 12 weeks, followed by once weekly for 36 weeks, n = unknown
Drug in study arm 4: Vehicle solution, 10% once daily for 12 weeks, followed by once weekly for 36 weeks, n = unknown
Outcomes Complete cure at week 52
Adverse events: reported
Notes Conference abstract of interim results so demographics limited. 1 of 6 authors has industry affiliation. Study supported by industry
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Quote: "patients have been randomised"
Comment: Method of randomisation not specified
Allocation concealment (selection bias) Unclear risk Comment: No information was available
Blinding of participants and personnel (performance bias) 
 All outcomes Unclear risk Comment: No information was available
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Comment: No information was available
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk Comment: No information was available
Selective reporting (reporting bias) Low risk Comment: Efficacy outcomes stated in trial protocol also stated in abstract. NCT01431820
Other bias Unclear risk Comment: Multiple treatment arms, but interim abstract of study's progress and no results to assess